Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Software developers entering the International Obfuscated C Code Contest must write programs that look baffling, but perform ...

Using the X-ray Polarimetry Explorer (IXPE) and Neutron star Interior Composition Explorer (NICER), Indian astronomers have ...

AI search startups Perplexity, You.com, and Liner have recruited hundreds of students to promote and endorse their apps.

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other cheap AI stocks to buy in 2025. Artificial Intelligence (AI) was a buzzword ...

This repository features DSA problems & solutions in Python adapted from structy.net course. I created it as a resource to help others enhance their problem-solving skills and build proficiency in ...

One of the features I am most excited about is the local search improvements. I had long given up on using Search in Windows as it was, to put it mildly, not great. These changes completely revamp ...

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (NASDAQ: RXRX) could be positioned to ride the ongoing wave of ...

Recursion Pharmaceuticals has a flashy drug development platform. It has a lot to prove about whether that platform's use of AI is helpful. Some power players have backed it with significant ...

Vivian DeWoskin, Chief Strategy Officer at Faro Health, Inc. Faro Health Inc., the leading AI-powered platform for data-driven clinical protocol design, today announced it has partnered with Recursion ...

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Recursion Pharmaceuticals ... and streamline your search for investment opportunities using Tipranks' Stock Screener ...